We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular medications such as Ozempic.

Imlunestrant worked particularly well in combination with the targeted therapy drug Verzenio. The combo helped women with ...

Ro, a telehealth company, has teamed up with Eli Lilly to improve patient access to Zepbound (tirzepatide). Through ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Zacks Research analyst K. Shah now forecasts that the company will post earnings of $4.69 per share for the quarter, down from […] ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.